The cobas 5800 System is a real-time PCR molecular testing solution that provides excellent performance and value-added utility from a compact footprint. Food and Drug Administration approval during Q3 2022. The cobas 5800 system, the newest member of the Roche Molecular Work Area, is built upon the innovation of the cobas ® 6800 and cobas ® 8800 systems, making molecular testing accessible to more patients around the world. This new system helps to address the high demands on labs through greater efficiency, optimised workflows and cost savings, enabling them to deliver quality patient care.” ”We are pleased that we can now offer a compact, fully-automated molecular system such as the cobas 5800 System.
“Diagnostics continue to revolutionise how providers care for patients, and it is essential, now more than ever, that the healthcare community has access to reliable and accurate testing solutions,” said Thomas Schinecker, CEO Roche Diagnostics. The cobas 5800 System helps address challenges that laboratories are facing from an increase in patient testing, reimbursement complexities and the need for a more diverse testing menu while providing meaningful and timely results. Testing is one of the first lines of defense to protect a patient’s general well-being and is vitally important in quickly guiding their treatment. The cobas 5800 System is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes so clinicians can quickly determine the best treatment strategies for their patients.īasel, 18 November 2021 - Roche (SIX: RO, ROG OTCQX: RHHBY) today announced the launch of the cobas ® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.Access to accurate and reliable diagnostic tests help clinicians improve patient care, limit healthcare spending and contribute to protecting public health.Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for millions of patients worldwide.
0 kommentar(er)
